Correction: Preventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study(BMC Pregnancy Childbirth, (2011), 11, 77, 10.11 86/1 471-2393-11-77)

Abstract

Correction: BMC Pregnancy Childbirth 11, 77 (2011) Following publication of the original article [1], the authors reported an error in Background section. “progesterone” should read “progestagens” in the following sentences: All highlighted instances of “progesterone” should be changed as indicated. “A breakthrough in the management of women at increased risk is the use of progesterone. Two randomized clinical trials demonstrated a reduction in preterm birth of 50% in women with a previous preterm birth [4, 5]. The number of women who delivered prior to 32 weeks in both studies decreased from 20–10%. The effectiveness of progesterone was also addressed in a recent meta-analysis [6]. Relative to women allocated to placebo, those who received progestational agents (17[alpha]-hydroxyprogesterone caproate and other forms of progesterone) had lower rates of preterm delivery (26% versus 36%), corresponding to a number needed to treat to prevent one premature delivery of 10. In addition, women who had received progestational agents had lower rates of perinatal mortality (14.8% versus 17.1%). The problem with the use of progesterone at present is that, based on current evidence, it can only be applied to women with a history of preterm birth.